High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.63M
-78.95%
-0.242
-189.57%
7.72M
-15.88%
-0.310
+6.8%
8.97M
+3.1%
-0.315
+1.73%
Estimates Revision
The market is revising Downward the revenue expectations for Wave Life Sciences Ltd. (WVE) for FY2025, with the revenue forecasts being adjusted by -7.53% over the past three months. During the same period, the stock price has changed by -8.08%.
Revenue Estimates for FY2025
Revise Downward
-7.53%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+3.34%
In Past 3 Month
Stock Price
Go Down
-8.08%
In Past 3 Month
12 Analyst Rating
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 18.09 USD with a low forecast of 9.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.620
Low
9.00
Averages
18.09
High
26.00
Current: 7.620
Low
9.00
Averages
18.09
High
26.00
Truist
Buy
maintain
$36
2025-10-29
Reason
Truist
Price Target
$36
2025-10-29
maintain
Buy
Reason
Truist reiterated a Buy rating and $36 price target on Wave Life Sciences after the company presented new data from its WVE-007 weight loss treatment study. WVE-007 could usher in a "new wave" of obesity therapeutics, with data showing a knockdown of Activin E in a dose-dependent manner that is squarely in "target range," the analyst tells investors in a research note. The firm noted, however, that the key unknown is how long of a follow-up may be needed in humans to see similar weight loss, and that it is widely understood that the data may need to mature to approach sema-like weight loss.
Clear Street
Bill Maughan
initiated
$22
2025-10-14
Reason
Clear Street
Bill Maughan
Price Target
$22
2025-10-14
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Wave Life Sciences with a Buy rating and $22 price target. The company has proven it can produce "first-in-class and best-in-class" genetic medicines, the analyst tells investors in a research note. The firm says Wave Life has a deep pipeline of attractive drug candidates, lead by WVE-007, which targets obesity.
Wells Fargo
Tiago Fauth
Overweight
maintain
$21 -> $18
2025-09-04
Reason
Wells Fargo
Tiago Fauth
Price Target
$21 -> $18
2025-09-04
maintain
Overweight
Reason
Wells Fargo analyst Tiago Fauth lowered the firm's price target on Wave Life Sciences to $18 from $21 and keeps an Overweight rating on the shares after the company reported AATD data update for 200 and 400 cohort. While the data support '006's MoA, they do not clearly answer whether '006 can increase M-AAT levels to the 11microM+ threshold most investors were hoping for and potential positioning vs competitive landscape/modalities.
B. Riley
B. Riley
Buy
maintain
$19
2025-09-04
Reason
B. Riley
B. Riley
Price Target
$19
2025-09-04
maintain
Buy
Reason
B. Riley reiterates a Buy rating on Wave Life Sciences with a $19 price target after the company announced RestorAATion-2 data. The data were positive and demonstrated first-ever therapeutic restoration of acute phase response in homozygous for the Z mutation alpha-1antitrypsin deficiency patients, the analyst tells investors in a research note. Riley believes the disclosure de-risks both WVE-006 and Wave Life's next RNA-editing candidate. It thinks RNA editing may be a safer alternative to gene editing, and sees a "material disconnect" between Wave Life's current valuation and its multi-asset probability-weighted commercial opportunity. The firm remains an "aggressive" buyer of the stock.
H.C. Wainwright
Andrew Fein
Buy
maintain
$22
2025-09-03
Reason
H.C. Wainwright
Andrew Fein
Price Target
$22
2025-09-03
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein says WVE-006's latest dataset confirms "robust," dose-dependent increases in functional M-AAT alongside meaningful reductions in pathogenic Z-AAT, but Wave's stock is down by nearly 20% despite the "encouraging" data, which the analyst calls an "overreaction to unjustified threshold value ascribed for total AAT and M AAT levels." These results strengthen the firm's conviction that WVE-006 can deliver both lung and liver benefit and the firm thinks the current data without the 400 mg MAD data "still shows an approval endpoint," according to the analyst, who has a Buy rating and $22 price target on Wave Life Sciences shares.
Leerink
Outperform
maintain
$24 -> $26
2025-09-03
Reason
Leerink
Price Target
$24 -> $26
2025-09-03
maintain
Outperform
Reason
Leerink raised the firm's price target on Wave Life Sciences to $26 from $24 and keeps an Outperform rating on the shares. Despite the impressive first demonstration of a dynamic acute phase response post-RNA editing in alpha-1-antitrypsin deficiency, Wave Life's stock performance suggests a greater increase in AAT protein was expected by the Street, the firm says. Leerink thinks investors should take advantage of this weakness to buy the stock ahead of additional important catalysts, which it remains optimistic investors will appreciate despite today's confusion.
See All Ratings
Valuation Metrics
The current forward P/E ratio for WAVE Life Sciences Ltd (WVE.O) is -6.53, compared to its 5-year average forward P/E of -5.03. For a more detailed relative valuation and DCF analysis to assess WAVE Life Sciences Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.03
Current PE
-6.53
Overvalued PE
-1.88
Undervalued PE
-8.18
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.86
Undervalued EV/EBITDA
-5.61
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
13.72
Current PS
0.00
Overvalued PS
22.57
Undervalued PS
4.87
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
WVE News & Events
Events Timeline
(ET)
2025-11-13
08:34:20
Korro's setback boosts Wave Life Sciences' standing, according to Jefferies.
2025-11-10 (ET)
2025-11-10
07:34:14
Wave Life Sciences announces Q3 earnings per share of 32 cents, surpassing consensus estimate of 30 cents.
2025-11-04 (ET)
2025-11-04
21:28:46
Wave Life Sciences to showcase preclinical findings highlighting the potential of WVE-007
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/23a6fc0364a4d88da7c25c1effd7df2578795e9e8f4ec20dd557a19f134a87d1.jpg)
Preview
9.5
11-13NASDAQ.COMAfter-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
9.5
11-12BenzingaAnalysts Update Their Predictions for Wave Life Sciences After Q3 Results
Preview
4.0
11-11BenzingaWells Fargo Keeps Overweight Rating on WAVE Life Sciences, Reduces Price Target to $16
Sign Up For More News
People Also Watch
FAQ
What is WAVE Life Sciences Ltd (WVE) stock price today?
What is WAVE Life Sciences Ltd (WVE)'s business?
What is the price predicton of WVE Stock?
What is WAVE Life Sciences Ltd (WVE)'s revenue for the last quarter?
What is WAVE Life Sciences Ltd (WVE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for WAVE Life Sciences Ltd (WVE)'s fundamentals?
How many employees does WAVE Life Sciences Ltd (WVE). have?